I always thank them because it's thanks to them."Jean-Claude has had no recurrence in three years, according to this phase 3 trial, carried out on more than 1,000 patients already operated on for melanoma.
Combined with immunotherapy, this new RNA vaccine reduced the risk of recurrence or death by 42% compared to immunotherapy administered alone.
This tailor-made treatment is carried out using specific mutations in the patient's tumor, to train their immune system to recognize and destroy cancer cells.
This innovative treatment is also currently being tested against lung, bladder and kidney cancer.
Jean-Claude, 78 years old, was able to benefit from it after having surgery for melanoma on the skull.
More than 30,000 oncologists from around the world will closely examine these results, which herald a real change in cancer treatments.
This new RNA vaccine, combined with immunotherapy, reduced the risk of recurrence or death by 42% compared to immunotherapy administered alone.
The results are good, the x-rays, the scanners, it's great.